D.J. v. UNIVERSITY OF IOWA HOSPITALS AND CLINICS

CourtDistrict Court, W.D. Pennsylvania
DecidedJune 30, 2024
Docket2:22-cv-00752
StatusUnknown

This text of D.J. v. UNIVERSITY OF IOWA HOSPITALS AND CLINICS (D.J. v. UNIVERSITY OF IOWA HOSPITALS AND CLINICS) is published on Counsel Stack Legal Research, covering District Court, W.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
D.J. v. UNIVERSITY OF IOWA HOSPITALS AND CLINICS, (W.D. Pa. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF PENNSYLVANIA

D.J., TONI CORDOVA, et al., ) ` ) Plaintiffs, ) ) Civil Action No. 2:22-752 v. ) ) UNIVERSITY OF IOWA HOSPITALS ) Judge Cathy Bissoon and CLINICS, et al., ) ) Defendants. )

MEMORANDUM AND ORDER I. MEMORANDUM

For the reasons stated below, the Motion to Dismiss (Doc. 133) Plaintiffs’ Second Amended Complaint filed by Defendants Ademola Abiose, Ann & Robert H. Lurie Children's Hospital of Chicago, Maryam Banikazemi, Baylor College of Medicine, Cedars-Sinai Medical Center, Joel Charrow, Children's Memorial Hospital, Cincinnati Children's Hospital, Columbia University Medical Center, Duke University Health Center, Christine Eng, Massachusetts General Hospital, Michael Mauer, Manesh Patel, Ronald Scott, Katherine Sims, University of Alabama at Birmingham Medicine, University of Iowa Hospitals and Clinics, University of Minnesota, University of Washington Medicine, David Warnock, William Wilcox (“Moving Defendants”)1 will be GRANTED.

1 The Moving Defendants include eleven medical centers (“Medical Center Defendants”) and their respective physicians (“Physician Defendants”). Four of the Medical Center Defendants – University of Iowa Hospitals and Clinics, University of Minnesota, University of Washington and University of Alabama at Birmingham – are public entities (“Public Entity Defendants”). The only two non-moving Defendants are foreign Defendants, Dominique Germain and the University of Versailles (“Foreign Defendants”). There is no reflection on the docket indicating that the Foreign Defendants have been served. A. Background

On September 30, 2023, this Court granted Moving Defendants’ Motion to Dismiss Plaintiffs’ First Amended Complaint for lack of personal jurisdiction. (Doc. 121). Specifically, the Court held that “there ha[d] been no showing that exercising personal jurisdiction over the Moving Defendants comports with Pennsylvania’s long-arm statute or that hauling the Moving Defendants into court in Pennsylvania would be fair, reasonable, or consistent with federal due process standards for specific jurisdiction.” Id. at 7–8. In its dismissal order, the Court afforded Plaintiffs the opportunity to file a Second Amended Complaint making last, best efforts to identify a valid jurisdictional basis for proceeding. See id. Plaintiffs filed their Second Amended Complaint on October 24, 2023, and have again failed to make that showing. (Doc. 124). On November 17, 2023, Defendants again moved to dismiss Plaintiffs’ Second Amended Complaint under Federal Rule of Civil Procedure 12(b)(2) for lack of personal jurisdiction. (Doc. 133). The Motion to Dismiss additionally seeks dismissal of the claims against the Public Entity Defendants, and their respective physicians, pursuant to Federal Rules of Civil Procedure

12(b)(1) and 12(b)(2), based on lack of standing and Eleventh Amendment immunity.2 Plaintiffs oppose Defendants’ Motion. (Doc. 135). This case is a putative class action brought by sixteen named Plaintiffs on behalf of themselves or their decedents, based on harm allegedly sustained as a result of a shortage of a drug called Fabrazyme that began in 2009 and lasted until 2012. Second Am. Compl. (Doc. 124)

2 As with the First Amended Complaint, Plaintiffs agree that Eleventh Amendment immunity applies to the Public Entity Defendants as to Counts 1-7 of the Second Amended Complaint, and, accordingly, did not name them as defendants as to those counts. Count 8 asserts an Interstate Compact Clause claim against only the Public Entity Defendants and their physicians in their official capacities. ¶¶ 1-16, 83-104. The alleged facts of the case are well known to the parties, and the Court recounts them only briefly here. Plaintiffs and/or their decedents suffered from Fabry disease, a rare, but lethal, heritable, genetic illness, in which a gene for an enzyme required to metabolize a certain fat is mutated or missing, resulting in the build-up of that fat in cells, blood vessels and

organs, resulting in inflammation and, ultimately, death. Id. ¶¶ 1-16, 68-70. Fabrazyme is a synthetic version of the enzyme that is infused every two weeks to treat Fabry disease and mitigate its effects. Id. ¶¶ 71-73. Fabrazyme manufacturer, Sanofi Genzyme Corporation, is the sole FDA-approved supplier of enzyme replacement therapy for Fabry disease in the United States market. Id. ¶¶ 77-80. The Physician Defendants did not treat any of the named Plaintiffs or their decedents; rather, they represented their respective medical institutions as members of the Fabry Stakeholder’s Working Group (“FSWG”), a group of experts convened by Sanofi Genzyme to prepare guidance to the Fabry community on the management of Fabrazyme supply during the drug shortage. Id. ¶¶ 105-129 and Exs. A, B. FWSG prepared two written guidance documents

containing recommendations for temporary reductions of Fabrazyme use in light of the shortage. Id. Ex. A (issued in July 2009), Ex. B (issued in or around September 2009). The Second Amended Complaint alleges that the Guidance was disseminated to all Fabry patients and their physicians, nationwide. Id. ¶¶ 116-120. The lawsuit essentially contends that Defendants, through their participation in the FSWG, intentionally initiated a harmful experimental medical protocol on Plaintiffs and collected research data on low-dose Fabrazyme efficacy without Plaintiffs’ informed consent.3

3 Counts 1-7 assert the following tort and constitutional claims against the non-public entity Defendants: (1) tort of failure to obtain informed consent; (2) breach of fiduciary duty; (3) Equal Protection violation (42 U.S.C. § 1981); (4) violation of 42 U.S.C. § 1983; (5) conspiracy to B. 12(b)(2) Motion to Dismiss – Lack of Personal Jurisdiction Under Federal Rule of Civil Procedure 12(b)(2), the plaintiff has the burden of pleading sufficient facts to establish that the court has personal jurisdiction over the defendants. See Pinker v. Roche Holdings, Ltd., 292 F.3d 361, 368 (3d Cir. 2002). When a defendant challenges

personal jurisdiction, “the plaintiff must ‘prove by affidavits or other competent evidence that jurisdiction is proper.’” Metcalfe v. Renaissance Marine, Inc., 566 F.3d 324, 330 (3d Cir. 2009) (quoting Dayhoff Inc.v. H.J. Heinz Co., 86 F.3d 1287, 1302 (3d Cir. 1996)). Absent jurisdictional discovery, however, a plaintiff need only “a prima facie case of personal jurisdiction,” and is entitled to have the allegations in the complaint taken as true and all factual disputes resolved in plaintiff’s favor. Miller Yacht Sales, Inc. v. Smith, 384 F.3d 93, 97 (3d Cir. 2004). Due process requires a finding of minimum contacts with Pennsylvania such that the exercise of personal jurisdiction “does not offend traditional notions of fair play and substantial justice.” O’Connor v. Sandy Lane Hotel Co., 496 F.3d 312, 316-17 (3d Cir. 2007). Personal

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Calder v. Jones
465 U.S. 783 (Supreme Court, 1984)
Marten v. Godwin
499 F.3d 290 (Third Circuit, 2007)
O'CONNOR v. Sandy Lane Hotel Co., Ltd.
496 F.3d 312 (Third Circuit, 2007)
Metcalfe v. Renaissance Marine, Inc.
566 F.3d 324 (Third Circuit, 2009)
Gaboury v. Gaboury
988 A.2d 672 (Superior Court of Pennsylvania, 2009)
Scoggins v. Scoggins
555 A.2d 1314 (Supreme Court of Pennsylvania, 1989)
Derman v. Wilair Services, Inc.
590 A.2d 317 (Superior Court of Pennsylvania, 1991)
Temtex Products, Inc. v. Kramer
479 A.2d 500 (Supreme Court of Pennsylvania, 1984)
Dayhoff Inc. v. H.J. Heinz Co.
86 F.3d 1287 (Third Circuit, 1996)
Miller Yacht Sales, Inc. v. Smith
384 F.3d 93 (Third Circuit, 2004)
Ford Motor Co. v. Montana Eighth Judicial Dist.
592 U.S. 351 (Supreme Court, 2021)
Christa Fischer v. Federal Express Corp
42 F.4th 366 (Third Circuit, 2022)
Nader Aldossari v. Joseph Ripp
49 F.4th 236 (Third Circuit, 2022)

Cite This Page — Counsel Stack

Bluebook (online)
D.J. v. UNIVERSITY OF IOWA HOSPITALS AND CLINICS, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dj-v-university-of-iowa-hospitals-and-clinics-pawd-2024.